Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anthrax Vaccine SDI
- Development stage
- Preclinical
- Lead developer
- Ligand Pharmaceuticals
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Anthrax Vaccine SDI is a solid-dose vaccine formulation developed by Glide Technologies in collaboration with Pfenex for the prevention of anthrax. The vaccine utilizes Glide's proprietary Solid Dose Injector (SDI) technology, which enables needle-free subcutaneous administration of the drug in a solid format. This approach is designed to enhance the stability of the vaccine, potentially removing the requirement for a cold chain during storage and distribution. The project was developed under a subcontract from Pfenex, aiming to leverage Pfenex's recombinant protein expression technology with Glide's delivery system to create a more stable and easily administered anthrax vaccine.
- Other names
- Anthrax vaccine
Beyond the preview
Go deeper on Anthrax Vaccine SDI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anthrax Vaccine SDI.